These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 33606496)

  • 1. To Push or To Pull? In a Post-COVID World, Supporting and Incentivizing Antimicrobial Drug Development Must Become a Governmental Priority.
    Cama J; Leszczynski R; Tang PK; Khalid A; Lok V; Dowson CG; Ebata A
    ACS Infect Dis; 2021 Aug; 7(8):2029-2042. PubMed ID: 33606496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial resistance research in a post-pandemic world: Insights on antimicrobial resistance research in the COVID-19 pandemic.
    Rodríguez-Baño J; Rossolini GM; Schultsz C; Tacconelli E; Murthy S; Ohmagari N; Holmes A; Bachmann T; Goossens H; Canton R; Roberts AP; Henriques-Normark B; Clancy CJ; Huttner B; Fagerstedt P; Lahiri S; Kaushic C; Hoffman SJ; Warren M; Zoubiane G; Essack S; Laxminarayan R; Plant L
    J Glob Antimicrob Resist; 2021 Jun; 25():5-7. PubMed ID: 33662647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial Resistance.
    Årdal C; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
    Clin Infect Dis; 2017 Oct; 65(8):1378-1382. PubMed ID: 29017240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Broken Antibiotic Market: Review of Strategies to Incentivize Drug Development.
    Bhavnani SM; Krause KM; Ambrose PG
    Open Forum Infect Dis; 2020 Jul; 7(7):ofaa083. PubMed ID: 32667365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance.
    Laxminarayan R; Impalli I; Rangarajan R; Cohn J; Ramjeet K; Trainor BW; Strathdee S; Sumpradit N; Berman D; Wertheim H; Outterson K; Srikantiah P; Theuretzbacher U
    Lancet; 2024 Jun; 403(10443):2534-2550. PubMed ID: 38797178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating The Appropriate Size Of Global Pull Incentives For Antibacterial Medicines.
    Outterson K
    Health Aff (Millwood); 2021 Nov; 40(11):1758-1765. PubMed ID: 34724432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance.
    Sciarretta K; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
    Clin Infect Dis; 2016 Dec; 63(11):1470-1474. PubMed ID: 27578820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards mission-driven investment in new antimicrobials? What role for Chinese strategic industrial financing vehicles in responding to the challenge of antimicrobial resistance?
    Husain L; Hu Y; Huang Y
    Global Health; 2024 Mar; 20(1):26. PubMed ID: 38532478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delineating the impact of COVID-19 on antimicrobial resistance: An Indian perspective.
    Seethalakshmi PS; Charity OJ; Giakoumis T; Kiran GS; Sriskandan S; Voulvoulis N; Selvin J
    Sci Total Environ; 2022 Apr; 818():151702. PubMed ID: 34798093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps.
    Simpkin VL; Renwick MJ; Kelly R; Mossialos E
    J Antibiot (Tokyo); 2017 Dec; 70(12):1087-1096. PubMed ID: 29089600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A narrative review on drug development for the management of antimicrobial- resistant infection crisis in Japan: the past, present, and future.
    Ohashi T; Nagashima M; Kawai N; Ohmagari N; Tateda K
    Expert Rev Anti Infect Ther; 2022 Dec; 20(12):1603-1614. PubMed ID: 36368311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coronavirus Disease 2019 and Antimicrobial Resistance: Parallel and Interacting Health Emergencies.
    Nieuwlaat R; Mbuagbaw L; Mertz D; Burrows LL; Bowdish DME; Moja L; Wright GD; Schünemann HJ
    Clin Infect Dis; 2021 May; 72(9):1657-1659. PubMed ID: 32544232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reinventing the antimicrobial pipeline in response to the global crisis of antimicrobial-resistant infections.
    Singer AC; Kirchhelle C; Roberts AP
    F1000Res; 2019; 8():238. PubMed ID: 30906539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How can lessons from the COVID-19 pandemic enhance antimicrobial resistance surveillance and stewardship?
    Walia K; Mendelson M; Kang G; Venkatasubramanian R; Sinha R; Vijay S; Veeraraghavan B; Basnyat B; Rodrigues C; Bansal N; Ray P; Mathur P; Gopalakrishnan R; Ohri VC
    Lancet Infect Dis; 2023 Aug; 23(8):e301-e309. PubMed ID: 37290476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interrelationships between antimicrobial resistance, COVID-19, past, and future pandemics.
    Ukuhor HO
    J Infect Public Health; 2021 Jan; 14(1):53-60. PubMed ID: 33341485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial resistance: A challenge awaiting the post-COVID-19 era.
    Lobie TA; Roba AA; Booth JA; Kristiansen KI; Aseffa A; Skarstad K; Bjørås M
    Int J Infect Dis; 2021 Oct; 111():322-325. PubMed ID: 34508864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial Resistance Threats in the emerging COVID-19 pandemic: Where do we stand?
    Ghosh S; Bornman C; Zafer MM
    J Infect Public Health; 2021 May; 14(5):555-560. PubMed ID: 33848884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotics and antimicrobial resistance in the COVID-19 era: Perspective from resource-limited settings.
    Lucien MAB; Canarie MF; Kilgore PE; Jean-Denis G; Fénélon N; Pierre M; Cerpa M; Joseph GA; Maki G; Zervos MJ; Dely P; Boncy J; Sati H; Rio AD; Ramon-Pardo P
    Int J Infect Dis; 2021 Mar; 104():250-254. PubMed ID: 33434666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial: The Global Threats of Increasing Antimicrobial Resistance Require New Approaches to Drug Development, Including Molecular Antimicrobial Adjuvants.
    Parums DV
    Med Sci Monit; 2024 Jul; 30():e945583. PubMed ID: 38967286
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.